Biology subjects

Irizarry, J.

Publications and source records attributed to Irizarry, J..

4 recordsLinked to original sources

bioRxiv2026

Multiomic State-Transitions Reveal Post-Treatment Transcriptome Desynchronization in Acute Myeloid Leukemia

Temporal dynamics of the peripheral blood transcriptome are crucial for understanding leukemia evolution and response to therapy because they can reveal how gene expression programs drive abnormal cell states, disease heterogeneity, and treatment resistance. Using a mathematical model of state-transitions, we studied the temporal dynamics of peripheral blood messenger RNA (mRNA) and microRNA (miRNA) transcriptomes in a mouse model of acute myeloid leukemia (AML). In our state-transition model, mRNA and miRNA transcriptomes are represented as a particle undergoing Brownian motion in a two-dimensional multiomic potential landscape. Following chemotherapy, we observed a temporal desynchronization between mRNA and miRNA transcriptomic responses corresponding to an asymmetric shift in the landscape. Specifically, mRNA trajectories responded almost immediately post-treatment, whereas miRNA responses were delayed by approximately two weeks. Clustering analysis identified that the temporal delay is driven by a prominent cluster of miRNAs from the imprinted Dlk1-Dio3 region. Although previously implicated in acute promyelocytic leukemia, lymphomas, and metabolic dysregulation, this provides the first evidence linking the Dlk1-Dio3 locus to AML chemotherapy response and treatment-induced transcriptomic desynchronization. This framework offers an innovative dynamics-based strategy to identify biological drivers of therapeutic response and novel therapeutic targets across hematological malignancies. Key PointsO_LITreatment can induce desynchronization between messenger RNA and microRNA transcriptome dynamics in a murine model of AML C_LIO_LIMicroRNAs from the imprinted Dlk1-Dio3 locus are identified as key contributors to desynchronization and may serve as therapeutic targets C_LI

cancer biology↗

bioRxiv2025

Overcoming treatment resistance mediated by the bone marrow vascular niche in acute myeloid leukemia

Acute myeloid leukemia (AML) is a hematologic malignancy originating in the bone marrow, frequently progressing to extramedullary sites. Despite advances in molecularly targeted therapies and hematopoietic stem cell transplantation, clinical outcomes remain suboptimal. Tyrosine kinase inhibitors (TKIs) confer benefit in a subset of AML patients harboring FLT3-ITD mutations, yet relapse and resistance are common. These failures are driven by both intrinsic properties of leukemic stem cells (LSCs)--a quiescent, self-renewing population--and extrinsic cues from the tumor microenvironment. We previously demonstrated that arteriolar endothelial cells (ECs) produce miR-126, which is transferred to LSCs, promoting quiescence, treatment resistance, and niche retention. During disease progression, TNF- secreted by expanding blasts suppresses EC miR-126 production, enabling LSCs and their progeny to proliferate. Following TKI administration, blast reduction lowers TNF- levels, restoring EC miR-126 production and enabling LSCs to re-enter quiescence--thereby escaping therapy and facilitating relapse. To investigate this dynamic, we developed an agent-based computational model of the AML bone marrow microenvironment, parameterized with in vitro and in vivo data. The model captures vascular niche remodeling and the feedback between leukemic populations and endothelial signaling. Simulations reveal that LSC protection mediated by miR-126 can be overcome by combining TKIs with miRisten, a miR-126 inhibitor. When administered on a defined schedule, this combination disrupts the protective niche and enhances LSC eradication. These findings underscore the therapeutic potential of targeting microenvironmental feedback to overcome resistance and prevent AML relapse.

cancer biology↗

bioRxiv2025

Longitudinal single cell RNA-sequencing reveals evolution of micro- and macro-states in chronic myeloid leukemia

Single cell RNA sequencing (scRNA-seq) has revolutionized our understanding of cancer, yet identifying meaningful disease states from single cell data remains challenging. Here, we systematically explore the chronic myeloid leukemia (CML) specific information content encoded in single cell versus bulk transcriptomics to resolve this paradox and clarify how discrete disease-defining states emerge from inherently noisy single cell data. We demonstrate that, while CML single cell transcriptomes exist along continuous transcriptional microstates, clinically relevant leukemia phenotypes clearly manifest only at the pseudobulk (macrostate) level. By leveraging state-transition theory, we reveal how robust disease phenotype state-transitions are governed by cell type specific contributions. Our results establish a theoretical framework explaining why discrete disease phenotypes remain hidden at the single cell scale but emerge clearly at the aggregated macrostate level, enabling previously inaccessible biological insights into leukemia evolution. By resolving how single-cell variation aggregates into macroscopic disease states, our framework provides new insight into CML progression and offers a broadly applicable strategy for exploring disease dynamics across cancers and other complex conditions.

systems biology↗

bioRxiv2021

High levels of Dorsal transcription factor downregulate, not promote, snail expression by regulating enhancer action

In Drosophila embryos, genes expressed along the dorsal-ventral axis are responsive to concentration of the Dorsal (Dl) transcription factor, which varies in space; however, levels of this morphogen also build over time. Since expression of high-threshold Dl target genes such as snail (sna) is supported before Dl levels peak, it is unclear what role increasing levels have if any. Here we investigated action of two enhancers that control sna expression in embryos, demonstrating using genome editing that Dl binding sites within one enhancer located promoter proximally, sna.prox, can limit the ability of the other distally-located enhancer, sna.dis, to increase sna levels. In addition, MS2-MCP live imaging was used to study sna transcription rate in wildtype, dl heterozygote, and a background in which a photo-sensitive degron is fused to Dl (dl-BLID). The results demonstrate that, when Dl levels are high, Dl acts through sna.prox to limit the activity of sna.dis and thereby influence sna transcription rate. In contrast, when Dl levels are kept low using dl-BLID, sna.prox positively influences sna transcription rate. Collectively, our data support the view that Dls effect on gene expression changes over time, switching from promoting sna expression at low concentration to dampening sna expression at high concentration by regulating enhancer interactions. We propose this differential action of the Dl morphogen is likely supported by occupancy of this factor first to high and then low affinity binding sites over time as Dl levels rise to coordinate action of these two co-acting enhancers. Significance statementA gradient of the maternal transcription factor Dorsal is important for establishing spatial expression of target genes along the dorsal-ventral axis of Drosophila embryos. Dorsal levels are also dynamic as nuclear concentration builds in time. Surprisingly, expression of high-threshold target genes such as snail is supported before levels peak, raising the question why levels continue to build. Our data support the view that peak Dorsal levels act to preferentially support activity of one enhancer over another to effectively decrease snail expression. In addition, while the morphogen Dorsal acts early to support gene expression, later it effectively acts as a damper to limit gene expression. Our results suggest other morphogens also have effects on gene expression that change over time.

developmental biology↗